NEW YORK, Feb. 07, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its fourth quarter and full year 2017 financial results prior to the NASDAQ market open on Wednesday, February 14, 2018. Intercept management will conduct a conference call and audio webcast on Wednesday, February 14, 2018 at 8:30 a.m. Eastern Time to discuss these results.
Intercept management will also be presenting at the following investor conferences:
- LEERINK Partners 7th Annual Global Healthcare Conference on February 15, 2018 at 2:00 p.m. Eastern Time
- 2018 RBC Capital Markets Global Healthcare Conference on February 21, 2018 at 10:00 a.m. Eastern Time
- 38th Annual Cowen Health Care Conference on March 12, 2018 at 2:10 p.m. Eastern Time
Webcast information for these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
Media inquiries: [email protected]
Investor inquiries: [email protected]


Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



